Also, even if HBV-associated HCCs influence the latter mutations, they are more significant in HCV-associated HCC (TERT), 60–80% in HCV-HCC vs. 30–40% in HBV-HCC; ARID2, 18% in HCV-HCC vs. 2% in HBV-HCC [87]. Here, ARID2 is linked to hepatocellular carcinoma.